|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 安德森博士癌症中心完全腹腔镜下广泛子宫根治术及淋巴结切除术经验显示文摘Objective.:To retrospectively evaluate the feasibility and morbidity of total laparoscopic radical hysterectomy and lymphadenectomy. Methods.:We performed a retrospective review of all patients who underwent a total laparoscopic radical hysterectomy at our institution between May 2004 and August 2005. Data collected included age,body mass index,stage,histopathologic subtype,tumor grade,estimated blood loss,perioperative blood transfusions,number and status of lymph nodes obtained,status of surgical margins,length of hospital stay,time to resumption of normal bladder function,intraoperative and postoperative complications,and disease-free interval. Results.:Twenty patients underwent total laparoscopic radical hysterectomy during the study period. None of the surgeries required conversion to laparotomy. The median patient age was 41.5 years (range,25-76). Eighteen patients had cervix cancer (5 stage IA2 and 13 stage IB1),and 2 had endometrial cancer (1 stage IB and 1 stage IIIA). Among those with cervix cancer,12 had adenocarcinoma,4 squamous cell carcinoma,and 2 adenosquamous carcinoma. The median weight was 70 kg (range,49-112). The median number of resected pelvic lymph nodes was 13 (range,9-26). One patient had nodal disease. The surgical margins were free of disease in all cases. The median blood loss was 200 ml (range,25-700 ml). Only 1 patient required an intraoperative blood transfusion (1 U packed red blood cells). The median length of hospital stay was 1 day (range,1-5). There were 3 short-term complications-unintentional cystotomy,pulmonary embolus,and pneumomediastinum with subcutaneous emphysema. There were 2 long-term complications-vaginal eviscerations and a lymphocyst. The median time to resumption of normal bladder function was 16 days (range,13-29). The median follow-up time was 8 months range (1-16). All patients remain free of disease at the time of this report. Conclusions.:Total laparoscopic radical hysterectomy can be performed safely with minimal blood loss and postoperative morbidity,and patients undergoing this proceduremay be discharged after an overnight stay in the hospital. | Ramirez P.T. Slomovitz B.M. Soliman P.T. 李欢 | 2006 | 世界核心医学期刊文摘(妇产科学分册)2006，0，12： | 2 |
| 2 | Coordinate ex-pression of CDC25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma butuncommon in high-grade endometrioid and nonendometrioid carcino-mas显示文摘 | Wu W Slomovitz BM Celestino J | 2003 | Cancer Res2003，63，19： | 1 |
| 3 | Uterine papillary serous carcinoma (UPSC):a single institution review of 129cases显示文摘 | Slomovitz BM Burke TW Eifel PJ | | 0，，03： | 1 |
| 4 | A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometria! carcinoma 显示文摘 | Slomovitz BM Lu KH Johnston T | 2010 | Cancer2010，116，23： | 1 |
| 5 | Shielded electronic currenttransformer 显示文摘 | SLOMOVITZ D de SOUZA H | 2005 | IEEE Trans on Instrumentation andMeasurement2005，54，2： | 1 |
| 6 | Uterine papillary serous carcinoma(UPSC) : a single institution review of 129 cases 显示文摘 | Slomovitz BM Burke TW Eifel PT | 2003 | Gynecol Oncol2003，91，3： | 1 |
| 7 | A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC) 显示文摘 | Slomovitz B Lu K H Johnston T | 2008 | J Clin Oncol2008，26，15： | 1 |
| 8 | Imatinib mesylate (gleevec) --targeted kinases are expressed in uterine sarcomas显示文摘 | Caudell JJ Deavers MT Slomovitz BM | 2005 | Appl Immunohistoehem Mol Morphol2005，13，2： | 1 |
| 9 | Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases显示文摘 | Soliman PT Slomovitz BM Broaddus RR | 2004 | Gynecol Oncol2004，94，： | 1 |
| 10 | Uterine papillary serous carcinoma(UPSC):a single institution review of 129 cases显示文摘 | Slomovitz BM Burke TW Eifel PJ | 2003 | Gynecol Oncol2003，91，： | 1 |
| 11 | Are women ready for the HPV vaccine显示文摘 | Slomovitz BM Sun CC Frumovitz M | 2006 | Gynecol Oncol2006，103，： | 1 |
| 12 | Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases 显示文摘 | Soliman PT Slomovitz BM Broaddus RR | 2004 | Gynaecol Oncol2004，94，2： | 1 |
| 13 | A phase II study of everolimus and letrozole in patients with recur- rent endometrial carcinoma显示文摘 | Slomovitz BM Brown J Johnston TA | 2011 | J Clin Oncol2011，29，： | 1 |
| 14 | Influence of resistance-temperature models of thermistors on the behaviour of linearizing circuits显示文摘 | Slomovitz Daniel Gomez Daniel | 1990 | International Journal of Electronics1990，69，5： | 1 |
| 15 | The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer显示文摘 | Slomovitz BM Coleman RL | 2012 | Clin Cancer Res2012，18，21： | 1 |
| 16 | Total laparo- scopic radical hysterectomy and lymphadenectomy:the MD anderson cancer center expefience显示文摘 | RamierzPT Slomovitz BM SolimanPT | 2006 | Gynecol Oncol2006，102，2： | 1 |
| 17 | Expression of imatinib mesylate-targeted kinases in endometrial carcinoma显示文摘 | Slomovitz BM Broaddus RR Schmandt R | 2004 | Gynecol Oncol2004，95，1： | 1 |
| 18 | A phase 2 study ot the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma 显示文摘 | Slomovitz BM Lu KH Johnston T | 2010 | Cancer2010，116，23： | 1 |
| 19 | Synchronous primary cancers of the endometrium and ovary,a single institution review of 84 cases显示文摘 | Soliman P T Slomovitz B M Broaddus R R | 2004 | Gynecologic Oncology2004，94，2： | 1 |
| 20 | Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia显示文摘 | Rubatt JM Slomovitz BM Burke TW | 2005 | Gynecol Oncol2005，99，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员